PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
Open Access
- 1 May 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (33) , 23208-23219
Abstract
Oncotarget | https://doi.org/10.18632/oncotarget.25292 Caroline Spasojevic, Elisabetta Marangoni, Sophie Vacher, Franck Assayag, Didier Meseure, Sophie Château-Joubert, Martine Humbert, Manale Karam, Jean Marc... PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancerKeywords
This publication has 32 references indexed in Scilit:
- Regulation of Protein Kinase D1 ActivityMolecular Pharmacology, 2012
- Targeted therapies for breast cancerJournal of Clinical Investigation, 2011
- Synthesis and Structure−Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase DACS Medicinal Chemistry Letters, 2010
- The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumorsJournal of Dermatological Science, 2010
- Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cellsBiochemical Journal, 2010
- Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motilityBMC Chemical Biology, 2010
- A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer GrowthIn vitroandIn vivoMolecular Cancer Therapeutics, 2010
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patientsBreast Cancer Research and Treatment, 2009
- Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasionBreast Cancer Research, 2009
- Potent and Selective Disruption of Protein Kinase D Functionality by a BenzoxoloazepinoloneJournal of Biological Chemistry, 2008